Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Rhodium Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102295582A reveals a novel rhodium-catalyzed three-component reaction for high-purity alpha-quaternary carbon diamino acids, offering significant cost reduction in API manufacturing.
Patent CN111138350B reveals a high-yield asymmetric synthesis route for dexchlorpheniramine, offering significant cost reduction and supply chain reliability for API manufacturers.
Patent CN1972898A details a novel Rh-catalyzed asymmetric hydrogenation process for unprotected beta-amino acids, offering significant cost reduction and streamlined API manufacturing.
Patent CN101346352B reveals efficient Rh-catalyzed asymmetric reduction for Mitiglinide. Offers high optical purity and industrial scalability for diabetes drug intermediates.
Patent CN101346352B reveals a novel rhodium-catalyzed asymmetric reduction for Mitiglinide intermediates, offering superior optical purity and industrial scalability for pharmaceutical manufacturers.
Patent CN103373948A details a high-yield 6-step asymmetric synthesis of (-)-Kainic Acid using Rh-catalysis, offering a reliable alternative to natural extraction for neuroscience research.
Efficient rhodium-catalyzed asymmetric cyclopropanation for antiviral drug intermediates. High enantioselectivity and scalable process for pharmaceutical manufacturing.
Advanced manufacturing of L-Phenylephrine HCl using optimized Rh-catalysis for high purity and cost-effective supply chain solutions.
Patent CN1160350C details a rhodium-catalyzed route for high-purity chiral lactones, offering significant cost reduction in API manufacturing and reliable supply chain continuity.
Discover the Rh-catalyzed asymmetric hydrogenation patent CN116444412A for chiral trifluoromethyl nitrogen heterocycles. Achieve high ee values and cost reduction in pharmaceutical intermediate manufacturing with scalable solutions.
Patent CN101175715B details Rh-catalyzed hydrogenation using PhanePhos for high-purity 3,3-diarylalanine intermediates, offering scalable API synthesis solutions.
Patent CN112824421A reveals a robust chiral ligand synthesis route offering high enantioselectivity and TON up to 10000 for pharmaceutical manufacturing.
Novel synthesis of chiral optical pure alkynylamide substituted α,β-diamino acid derivatives via Rh-catalyzed three-component reaction for potent anticancer applications.
Patent CN109678911B details a high-efficiency Rh-catalyzed method for planar chiral ferrocene intermediates, offering superior enantioselectivity and supply chain reliability.
Novel Rh-catalyzed C-H activation method for high-purity axial chiral intermediates with superior enantioselectivity and scalable process efficiency.
Novel Rh-catalyzed asymmetric hydrogenation avoids resolution, boosting yield to 42.55% for reliable API intermediate supply.
Patent CN111196791B reveals a novel Rh-catalyzed route to chiral gamma-butyrolactones with high enantioselectivity, offering cost-effective API intermediate solutions.